 |
|
|
| |
ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients With History of Depression or Bipolar Disorder: Pooled Analysis of Efficacy and Safety in Phase 3 Trials
|
| |
| |
Reported by Jules Levin
AASLD Nov 7-11 2014 Boston
David R Nelson1, K Rajender Reddy2, Peter Ferenci3, Darrell Crawford4, Rudolf E Stauber5, Alexey Yakovlev6, Victor de Ledinghen7, Holger Hinrichsen8, David Bernstein9, Robert J de Knegt10,
Tarek Hassanein11, Suzanne Norris12, Bo Fu13, Barbara McGovern13, Kosh Agarwal14
1Department of Medicine, University of Florida, Gainesville, Florida, United States; 2University of Pennsylvania, Philadelphia, Pennsylvania, United States; 3Universitätsklinik fur Innere Medizin III, Vienna, Austria; 4Gallipoli Medical Research Foundati on & The University of Queensland, Brisbane,
Australia; 5Department of Internal Medicine, Medical University of Graz, Graz, Austria; 6Clinical Infecti ous Diseases Hospital na SP Botkin, St. Petersburg, Russia; 7Hopital Haut Lévêque, CHU Bordeaux, Pessac, France;
8Gastroenterologisch-Hepatologisches Zentrum, Kiel, Germany;
9North Shore University Hospital, Manhasset, New York, United States; 10Erasmus MC, Rott erdam, the Netherlands; 11Southern California Liver Centers and Southern California Research Center, Coronado, California, United States; 12St. James's Hospital, Dublin, Ireland;
13AbbVie Inc., North Chicago, Illinois, United States; 14Institute of Liver Studies, Kings College Hospital, London, United Kingdom
|
| |
|
|
|
|
|
